Skip to search formSkip to main contentSkip to account menu

NCX1000

Known as: NCX 1000, NCX-1000 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
NCX-1000, a Nitric Oxide–Releasing Derivative of UDCA, Does Not Decrease Portal Pressure in Patients With Cirrhosis: Results of a Randomized, Double-Blind, Dose-Escalating Study
OBJECTIVES:NCX-1000 (2(acetyloxy) benzoic acid-3(nitrooxymethyl)phenyl ester) is an nitric oxide (NO)-releasing derivative of… 
Review
2008
Review
2008
Organization of the core structure of the postsynaptic density (Proceedings of the National Academy of Sciences of the United States of America (2008) 105, 11 (4453-4458) DOI: 10.1073/pnas.0800897105…
EDITORIAL EXPRESSION OF CONCERN. PNAS is publishing an Editorial Expression of Concern regarding the following three articles: (i… 
2007
2007
Combining ursodeoxycholic acid or its NO-releasing derivative NCX-1000 with lipophilic antioxidants better protects mouse hepatocytes against amiodarone toxicity.
Nonalcoholic steatohepatitis (NASH) is a common and potentially severe form of liver disease. This study aimed to determine the… 
2004
2004
Liver delivery of NO by NCX‐1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice 
THIS ARTICLE HAS BEEN RETRACTED
NCX‐1000, (3α, 5β, 7β)‐3,7‐dihydroxycholan‐24oic acid[2‐methoxy‐4‐[3‐[4‐(nitroxy)butoxy]‐3‐oxo‐1‐propenyl]phenyl ester, is a… 
Review
2004
Review
2004
Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status.
Portal hypertension, a life threatening complication of liver cirrhosis, results from increased intrahepatic resistance and… 
Highly Cited
2003
Highly Cited
2003
NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver…
Highly Cited
2003
Highly Cited
2003
A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats.
Highly Cited
2001
Highly Cited
2001
NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension
Portal hypertension resulting from increased intrahepatic resistance is a common complication of chronic liver diseases and a… 
Highly Cited
2001
Highly Cited
2001
An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity
Caspases are key mediators in liver inflammation and apoptosis. In the present study we provide evidence that a nitric oxide (NO… 
2001
2001
NCX-1000, an NO derivative of UDCA, refeases NO and protects against portal hypertension by inhibiting hepatic stellate cell contraction
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License